Interim report January-March 2005

• Sales increased by 3 percent, to SEK 30.5 (29.5) million. Adjusted for exchange-rate effects the increase was 6 percent. • Gross income amounted to SEK 20.6 (20.5) million and the gross margin to 67 percent (69). • Operating income amounted to SEK 5.4 (5.4) million. • Net income for the Group was SEK 6.2 (6.1) million. • Earnings per share amounted to SEK 0.34 (0.33). • The equity/assets ratio increased to 83 percent (78). • Sale of the shares in Cellartis AB has led to a capital gain of SEK 2.4 million. • Sales approval has been obtained for ICSI™ in the USA. • A patent concerning the use of alanyl-glutamine in media for embryos and stem cells has been approved in the USA. • Powerful measures have been taken during the period with regard to marketing, R&D and the expansion of production capacity. May 10, 2005 Kungsbacka, Sweden Magnus Nilsson CEO Questions should be addressed to: Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61. Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

---